Our Pipeline

We are advancing the science and our approach through the following programs.

Program
Indication
Discovery
Validation
IND Enabling
Clinical

SBT-77-7101

Sonoma Bio logoA novel regulatory T cell-based therapy for patients with rheumatoid arthritis.

An autologous (using the patient’s own cells) Treg cell therapy to target proteins in the inflamed joints of RA patients, with the aim to dampen inflammation and restore balance to the immune system.

SBT-77-7200 Series

Engineered regulatory T cell-based therapeutics for patients with IBD and other diseases.

SBT-11-5301

An effector T Cell-modulating biologic for autoimmune diseases.

SBT-11-5301 is a biologic designed to eliminate highly activated effector T cells (Teff) that are dominant in autoimmune and inflammatory disease.

Istock 1189303727 Aspect Ratio 1559 1413

Partnerships

We are always looking for the right academic and industry partners.